Direct answer. In the 2026 Phase 2b paper, 50 of 52 CBL-514 recipients and 44 of 55 placebo recipients in the safety population reported at least one treatment-emergent adverse event. The numbers require their placebo comparator, event type and severity; they do not establish safety for a separate research vial.
Start with the 107 people in the safety table
The 2026 randomized Phase 2b paper reports 108 adults randomized, while its Table 2 uses a safety population of 52 people in the CBL-514 group and 55 in the placebo group. These are the denominators for the adverse-event percentages on that page. At least one treatment-emergent adverse event was reported by 50/52 (96.2%) and 44/55 (80.0%), respectively. The term covers events arising after treatment; it does not by itself say that the study drug caused each one.
The same table lists injection-site pain in 38/52 (73.1%) versus 20/55 (36.4%) and bruising in 37/52 (71.2%) versus 28/55 (50.9%). Both groups had local events, so omitting placebo creates a distorted picture. The publication provides additional categories and follow-up detail; a short selection should be labelled as such. Its efficacy responder fractions use different analyzed groups and cannot replace the safety denominators.
Evidence check
- Safety population: CBL-514 n=52; placebo n=55.
- Any treatment-emergent event: 50/52 versus 44/55.
- Selected local events: pain 38/52 versus 20/55; bruising 37/52 versus 28/55.
Severity, seriousness and discontinuation answer different questions
Table 2 classifies the highest reported intensity for each participant as mild, moderate or severe. Severe events appear in 5/52 (9.6%) CBL-514 recipients and 2/55 (3.6%) placebo recipients. “Severe” describes intensity; it is not interchangeable with “serious,” which is a separate category tied to outcomes such as hospitalization or disability under FDA-hosted ICH safety definitions. The paper reports two serious treatment-emergent events, fractures in one person per group, judged unrelated to study treatment.
Discontinuation is another distinct measure. Five participants stopped because of treatment-emergent events: four in the CBL-514 group and one in placebo. The four active-group cases were three injection-site urticaria events and one injection-site pain event. These facts belong beside any sentence saying the agent was “well tolerated.” They also show why an abstract phrase cannot stand in for the full safety section: readers need the severity table, attribution and reasons for stopping to understand the authors’ conclusion.
Evidence check
- Severe intensity: 5/52 versus 2/55.
- Serious events: one fracture in each group, judged unrelated.
- Event-related discontinuations: four versus one.
What this trial can and cannot say about risk
The paper studied a selected abdominal-fat population under a defined investigational protocol and followed participants for approximately 25 weeks including screening, treatment and follow-up. It reports no life-threatening or fatal treatment-emergent events in that study, while most reported events were local. That observation is bounded by the study size, eligibility rules and observation window. It is not a zero-risk estimate for wider populations, other indications or longer periods. The NCT05736107 record provides the registered study context; use the paper for the reported event counts.
A 2025 Phase II report also describes injection-site reactions, but its safety population, design and follow-up differ. Combining percentages from the two papers as though they were one pooled safety estimate would be misleading. The published development program concerns a small-molecule agent despite the “CBL-514 peptide” search phrase. Neither publication verifies an independently offered powder or its batch identity. For procurement, keep the clinical literature next to, but separate from, the batch certificate review and material specification. This page is a guide to reading published evidence, not administration advice.
Evidence check
- Context: one abdominal-fat Phase 2b study with defined follow-up.
- Do not pool different trials without a justified method.
- Clinical safety data do not establish the contents of a third-party vial.
Reviewed 24 October 2026. This article summarizes published research; it gives no treatment or administration instructions. The clinical development program is independent of this website.
Frequently asked questions
How many people were in the 2026 CBL-514 safety analysis?
Table 2 uses 52 CBL-514 recipients and 55 placebo recipients. Its percentages are calculated from those groups, even though the paper describes 108 people randomized overall.
Were all reported events attributed to CBL-514?
No. A treatment-emergent event occurs after treatment, but timing alone does not establish causation. The paper reports local events in both groups and discusses treatment-related events separately.
Are severe and serious adverse events the same?
No. Severe describes intensity. Serious is a separate outcome-based regulatory category. In this trial, five active-group participants had a severe event; the two reported serious events were fractures, one in each group, judged unrelated to treatment.
Do these results establish the safety of a research-use vial sold elsewhere?
No. The paper concerns the investigational formulation and enrolled participants. A separate vial needs its own identity, composition and batch evidence; clinical findings cannot be transferred by a shared name.